Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Changhai Hospital
• Treatments: Butylscopolammonium Bromide; Drotaverin; Papaverine; Scopolamine; Scopolamine Hydrobromide

Criteria

Inclusion Criteria:

• All patients undergoing ERCP above the age of 18 years

Exclusion Criteria:

• Patient with Billroth II gastrectomy

• Known previous sphincterotomy

• Active acute pancreatitis before ERCP

• Ongoing acute cholangitis before ERCP

• Hypotension (systolic blood pressure < 100 mmHg)

• Second-degree and third-degree atrioventricular block

• Heart failure

• Glaucoma

• Obstructive uropathy

• Impaired renal function (serum creatinine > 133μmol/L)

• Pregnant or breastfeeding women